Installs a commercial lyophiliser for 2ml and 50ml vials
Kemwell Biopharma, a global contract development and manufacturing services provider with manufacturing in Bangalore, India, and Uppsala, Sweden, has added a GMP lyophilisation capability to its sterile injectable offering for biologics and pharmaceuticals.
The company has installed a 7.5m2 commercial lyophiliser equipped with a CIP and SIP facility. It will produce batch sizes from 4,000 (50ml vial) to 29,000 (2ml vial).
With this new capability, Kemwell now offers a complete range of services from lyo-cycle development, through small-scale manufacturing for pre-clinical studies to GMP manufacturing of lyophilised vials for clinical and commercial products.
Anurag Bagaria, Chairman and Managing Director of Kemwell Biopharma, commented: \'The outsourcing of services in the bio/pharmaceutical industry is growing and Kemwell will continue to invest in technologies to support our customers\' needs.\'
Founded in 1980, Kemwell now employs 1,200 people, has 10 facilities worldwide and supplies to 80 countries globally.